107 related articles for article (PubMed ID: 12031830)
1. Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031).
Post JM; Sullivan ME; Abendschein D; Ewing J; Hinchman JW; Light DR
Thromb Res; 2002 Feb; 105(4):347-52. PubMed ID: 12031830
[TBL] [Abstract][Full Text] [Related]
2. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
Chi L; Pen YW; Potoczak R; Gibson G; Hicks G; Mertz TE; Janiczek N; Juneau PL; Gallagher K; Leadley R
Pharmacology; 2002 Feb; 64(2):76-83. PubMed ID: 11803247
[TBL] [Abstract][Full Text] [Related]
3. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
McClanahan TB; Hicks GW; Morrison AL; Peng YW; Janiczek-Dolphin N; Mertz TE; Sullivan ME; Morser J; Juneau PL; Leadley R
Eur J Pharmacol; 2001 Dec; 432(2-3):187-94. PubMed ID: 11740955
[TBL] [Abstract][Full Text] [Related]
4. Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
Karnicki K; McBane RD; Miller RS; Leadley RJ; Morser J; Owen WG; Chesebro JH
J Thromb Haemost; 2004 Dec; 2(12):2162-9. PubMed ID: 15613022
[TBL] [Abstract][Full Text] [Related]
5. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
6. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of a novel factor Xa inhibitor, RPR 130737.
Chu V; Brown K; Colussi D; Choi YM; Green D; Pauls HW; Spada AP; Perrone MH; Leadley RJ; Dunwiddie CT
Thromb Res; 2000 Jul; 99(1):71-82. PubMed ID: 11012377
[TBL] [Abstract][Full Text] [Related]
8. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
[TBL] [Abstract][Full Text] [Related]
9. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Abendschein DR; Baum PK; Martin DJ; Vergona R; Post J; Rumennik G; Sullivan ME; Eisenberg PR; Light DR
J Cardiovasc Pharmacol; 2000 May; 35(5):796-805. PubMed ID: 10813384
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood.
Kaiser B; Jeske W; Walenga JM; Fareed J
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):495-501. PubMed ID: 10636461
[TBL] [Abstract][Full Text] [Related]
11. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro.
Hauptmann J; Kaiser B
Blood Coagul Fibrinolysis; 1993 Aug; 4(4):577-82. PubMed ID: 8218854
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
14. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Tobu M; Iqbal O; Hoppensteadt DA; Shultz C; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2002 Oct; 8(4):325-36. PubMed ID: 12516682
[TBL] [Abstract][Full Text] [Related]
15. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
Abendschein DR; Baum PK; Verhallen P; Eisenberg PR; Sullivan ME; Light DR
J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
[TBL] [Abstract][Full Text] [Related]
16. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Morishima Y; Kamisato C
Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
[TBL] [Abstract][Full Text] [Related]
17. Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
Ieko M; Tarumi T; Takeda M; Naito S; Nakabayashi T; Koike T
J Thromb Haemost; 2004 Apr; 2(4):612-8. PubMed ID: 15102016
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
Qiu X; Wang W; Zhao Z; Sun S; Tang L
Eur J Pharmacol; 2018 Oct; 836():50-56. PubMed ID: 30125563
[TBL] [Abstract][Full Text] [Related]
19. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles.
Furugohri T; Isobe K; Honda Y; Kamisato-Matsumoto C; Sugiyama N; Nagahara T; Morishima Y; Shibano T
J Thromb Haemost; 2008 Sep; 6(9):1542-9. PubMed ID: 18624979
[TBL] [Abstract][Full Text] [Related]
20. Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Abendschein DR; Baum PK; Light DR; Morser J
J Thromb Haemost; 2003 Sep; 1(9):1955-8. PubMed ID: 12941036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
